CLINICAL TRIALS PROFILE FOR VANCERIL DOUBLE STRENGTH
✉ Email this page to a colleague
All Clinical Trials for VANCERIL DOUBLE STRENGTH
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00489203 ↗ | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | Completed | Fred Hutchinson Cancer Research Center | Phase 2 | 2007-04-01 | RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VANCERIL DOUBLE STRENGTH
Condition Name
Condition Name for VANCERIL DOUBLE STRENGTH | |
Intervention | Trials |
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | 1 |
Contiguous Stage II Adult Lymphoblastic Lymphoma | 1 |
Stage III Small Lymphocytic Lymphoma | 1 |
Recurrent Adult Acute Myeloid Leukemia | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Condition MeSH
Clinical Trial Locations for VANCERIL DOUBLE STRENGTH
Trials by Country
Clinical Trial Progress for VANCERIL DOUBLE STRENGTH
Clinical Trial Phase
Clinical Trial Sponsors for VANCERIL DOUBLE STRENGTH
Sponsor Name